DEFA14A ·Filed Apr 27, 2026

AGL

agilon health, inc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago SEC0001628280-26-027515
Proxy solicitation materials
Actionable Insight • Neutral

The supplement is administrative and does not change voting. The annual meeting is on June 2, 2026; no immediate trading action required. Monitor for any activist developments given the proxy fight context.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
AGL ▲ +259.39% at T+60d
NEUTRAL call ✓ call won +259.39% · α vs SPY +255.40% · entry $27.90 → $100.27
Entry anchored
Apr 27, 03:59 PM ET
via exchange tick
T+1d
-8.46%
call -8.46% · α -8.45%
$25.54
settled 5mo ago
T+5d
-3.44%
call -3.44% · α -5.13%
$26.94
settled 5mo ago
T+20d
+205.63%
call +205.63% · α +200.16%
$85.27
settled 4mo ago
T+60d
+259.39%
call +259.39% · α +255.40%
$100.27
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Agilon health filed a supplement to its proxy statement clarifying the appointment of Tim O'Rourke as CEO, President, and Class III Director. The supplement does not change any proposals or board recommendations for the June 2, 2026 annual meeting. This is a routine disclosure following the previously announced CEO appointment.

Key Facts

  • Tim O'Rourke appointed CEO and President, effective May 7, 2026.
  • O'Rourke also appointed as Class III Director, term expiring at 2027 annual meeting.
  • Compensation includes $850,000 base salary, $500,000 signing bonus, 120,000 RSUs, and 200,000 PSUs with stock price targets ($50, $100, $150).
  • Supplement does not alter proposals or board recommendations for the June 2, 2026 annual meeting.

Financial Impact

Executive compensation package: $850,000 base salary, $500,000 signing bonus, 120,000 RSUs, and 200,000 PSUs.

executive compensation

Risk Factors

  • Potential shareholder dissent if compensation is viewed as excessive given stock performance.
  • Proxy fight context may lead to heightened governance scrutiny.

Market Snapshot

Exchange
NYSE
Sector
Services-Misc Health & Allied Services, NEC
Analyst Consensus
8% bullish (24 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001628280-26-027515
Document: 0001628280-26-027515-index-headers.html0001628280-26-027515
Document: 0001628280-26-027515-index.html0001628280-26-027515
Document: 0001628280-26-027515.txt0001628280-26-027515
4 reports for AGL
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for AGL — sortable, filterable
TypeNow
Apr 27, 2026
22w ago
DEFA14A
NEUTRAL ★ 2/10
$27.90 $100.27▲ +259.39%▲ +255.40%$84.63 (+203.33%)
Apr 27, 2026
22w ago
8-K
NEUTRAL ★ 4/10
$27.90 $100.27▲ +259.39%▲ +255.40%$84.63 (+203.33%)
Feb 28, 2026
30w ago
Institutional Cluster
BULLISH ★ 6/10
$15.40 $85.27▲ +453.70%▲ +444.37%$84.63 (+449.55%)
Feb 25, 2026
31w ago
8-K
MIXED ★ 6/10
$12.50 $80.94▲ +547.52%▲ +540.57%$84.63 (+577.04%)
Showing 4 of 4

US Market Status

Market Open — Closes in 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access